. Author manuscript; available in PMC: 2022 Feb 17.

Published in final edited form as: Lancet Diabetes Endocrinol. 2021 Aug 24;9(11):767–775. doi: 10.1016/S2213-8587(21)00178-9

Table 1.

Epidemiology and clinical presentation of patients with adrenal myelolipomas.

	Population-based or nationwide cohorts^2,3	Endocrine clinic and radiology referral cohort^13,39–41	Adrenalectomy cohort^{3,13,29,42–51}	Congenital adrenal hyperplasia11
Proportion of all adrenal tumours	3.3–3.6%	1.8–6.5%	4–10% of all adrenal tumours 15–20% of large adrenal tumours > 4 cm	25.4% (all CAH) 36.6% (genetically verified CAH)
Proportion of benign adrenal tumours	3.7%	-	-	Same as above
Median age at diagnosis, years	-	60–65	50–55	44
Female sex	-	45%	35–75%	35.7%
*Mode of discovery:* Incidental Symptoms of mass effect Other	95% 0% 5%	86% 5% 9%	35–70% 20–50% 2–5%	Almost all occur due to poor hormonal control with either incidental discovery, or based on symptoms of mass effect
Median tumour size at diagnosis	-	2 – 4 cm	5–7 cm	10.2 cm
Bilateral Unilateral	-	5% 95%	5–10% 90–95%	59.6% 40.4%

CAH, congenital adrenal hyperplasia.